Researchers have developed and tested a new tool that searches for the most common genetic anomalies seen in cancer. The assay demonstrates the ability to make gene sequencing easier over a large volume of samples. In the future, this may mean that patients would not always need to undergo a fresh biopsy in order to identify a potential treatment strategy, as is currently necessary with more comprehensive sequencing approaches.
In certain types of cancer, nerves and cancer cells enter an often lethal and intricate waltz where cancer cells and nerves move toward one another and eventually engage in such a way that the cancer cells enter the nerves.
Lisa A. Newman, M.D., M.P.H., director of the Breast Care Center, is one of seven University of Michigan faculty members to receive the 2015 Harold R. Johnson Diversity Service Award from the Office of the Provost.
One of Ann Arbor’s most exciting educational events is back. One Day Closer gives individuals and families an up-close look at one of the world’s leading cancer research facilities and what its internationally-recognized scientists and colleagues are doing to discover the cure for cancer.
Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.
Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.